Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01253668 · ClinicalTrials.gov registry record · Phase 2
Brivanib Metastatic Renal Cell Carcinoma
A Phase 2 study, sponsored by Abramson Cancer Center at Penn Medicine.
- Terminated
- Registry status
- Phase 2
- Development phase
- 10
- Enrollment target
NCT01253668 is a Phase 2 study that was terminated before completion, run by Abramson Cancer Center at Penn Medicine. The registered enrollment target is 10 participants.
The verdict
NCT01253668, a Phase 2 study, was terminated before completion, sponsored by Abramson Cancer Center at Penn Medicine.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 10 participants
- Enrollment target
Study Summary
This is a phase II study of an investigational agent, brivanib, in patients with refractory metastatic renal cell carcinoma. This study will evaluate the safety and effectiveness of brivanib in renal cell carcinoma, and explore the activity of this drug in this population to determine whether imaging and molecular features of the tumors can be used to predict response. Approximately 30 people with advanced kidney cancer will be enrolled on this study at the University of Pennsylvania.
Interventions
- GENETIC Protein expression analysis
- DRUG Brivanib alaninate
- GENETIC Polymerase chain reaction
- OTHER Iodine I 124 chimeric monoclonal antibody G250
- PROCEDURE Positron emission tomography/computed tomography
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 10 participants |
| Start Date | 2011-11 |
| Est. Completion | 2013-09 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01253668
The ClinicalTrials.gov registry entry for NCT01253668 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 10 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Abramson Cancer Center at Penn Medicine, which has 402 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Protein expression analysis is the first listed.
NCT01253668 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01253668 about?
NCT01253668 is a clinical study titled "Brivanib Metastatic Renal Cell Carcinoma". This is a phase II study of an investigational agent, brivanib, in patients with refractory metastatic renal cell carcinoma. This study will evaluate the safety and effectiveness of brivanib in renal cell carcinoma, and explore the activity of this drug in this population to determine whether imagin...
What is the current status of trial NCT01253668?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 10 participants. The study started on 2011-11. Estimated completion is 2013-09.
What interventions are being tested in trial NCT01253668?
The interventions under investigation include: Protein expression analysis (GENETIC), Brivanib alaninate (DRUG), Polymerase chain reaction (GENETIC), Iodine I 124 chimeric monoclonal antibody G250 (OTHER), Positron emission tomography/computed tomography (PROCEDURE).
Who is sponsoring clinical trial NCT01253668?
This trial is sponsored by Abramson Cancer Center at Penn Medicine, which has 402 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.